CD16xCD33 BiKE enhances MDS-NK cell function against CD33⁺ targets. Resting PBMCs from normal donors and MDS patients were coated with 10 μg/mL of the CD16xCD33 BiKE or scFv CD16 control and cocultured with (A-C) or without (D-F) CD33⁺ HL-60 targets. NK cell CD107a expression and intracellular TNF-α and IFN-γ production were evaluated by FACS analysis (*P < .05, **P < .01, ***P < .001, ****P < .0001).